{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:20:05Z","timestamp":1761895205556},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2010,12,6]],"date-time":"2010-12-06T00:00:00Z","timestamp":1291593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,12,6]],"date-time":"2010-12-06T00:00:00Z","timestamp":1291593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1038\/bmt.2010.315","type":"journal-article","created":{"date-parts":[[2010,12,6]],"date-time":"2010-12-06T12:10:53Z","timestamp":1291637453000},"page":"1418-1425","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes"],"prefix":"10.1038","volume":"46","author":[{"given":"J","family":"Perkins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Field","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M A","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Fancher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Tate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L M","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M C","family":"Milone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Anasetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,6]]},"reference":[{"key":"BFbmt2010315_CR1","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","volume":"8","author":"JA Russell","year":"2002","unstructured":"Russell JA, Tran HT, Quinlan BN, Chaudhry A, Duggan P, Brown C et al. Once daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468\u2013476.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010315_CR2","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1182\/blood-2002-11-3567","volume":"102","author":"M Bornhauser","year":"2003","unstructured":"Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102: 820\u2013826.","journal-title":"Blood"},{"key":"BFbmt2010315_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","volume":"104","author":"M De Lima","year":"2004","unstructured":"De Lima M, Couriel D, Thall PF, Wang Z, Madden T, Jones R et al. Once daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857\u2013864.","journal-title":"Blood"},{"key":"BFbmt2010315_CR4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","volume":"13","author":"BS Andersson","year":"2008","unstructured":"Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS. Biol Blood Marrow Transplant 2008; 13: 672\u2013684.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010315_CR5","first-page":"225","volume":"17","author":"SP Dix","year":"1996","unstructured":"Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225\u2013230.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010315_CR6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/sj.bmt.1700994","volume":"20","author":"P Ljungman","year":"1997","unstructured":"Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G . High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997; 20: 909\u2013913.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010315_CR7","first-page":"31","volume":"16","author":"JT Slattery","year":"1995","unstructured":"Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31\u201342.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010315_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","volume":"8","author":"BS Andersson","year":"2002","unstructured":"Andersson BS, Couriel D, Madden T, Couriel D, Wang X, Tran HT et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft vs host disease; defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477\u2013485.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010315_CR9","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","volume":"89","author":"JT Slattery","year":"1997","unstructured":"Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055\u20133060.","journal-title":"Blood"},{"key":"BFbmt2010315_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1053\/bbmt.2002.v8.pm12374454","volume":"8","author":"A Kashyap","year":"2002","unstructured":"Kashyap A, Wingard J, Cagnoni P, Jones R, Tarantolo S, Hu W et al. Intravenous versus oral busulfan as part of a busulfan\/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002; 8: 493\u2013500.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010315_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2002-08-2619","volume":"102","author":"JP Radich","year":"2003","unstructured":"Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003; 102: 31\u201335.","journal-title":"Blood"},{"key":"BFbmt2010315_CR12","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmeier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912\u20132919.","journal-title":"Blood"},{"key":"BFbmt2010315_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.bbmt.2008.12.509","volume":"15","author":"JW Chein","year":"2009","unstructured":"Chein JW, Sullivan KM . Carbon monoxide diffusion capacity: How low can you go for hematopoietic cell transplantation eligibility? Biol Blood Marrow Transplant 2009; 15: 447\u2013453.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010315_CR14","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1093\/clinchem\/44.12.2506","volume":"44","author":"WK Lai","year":"1998","unstructured":"Lai WK, Pang CP, Law LK, Wong R, Li CK, Yuen PM . Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. Clin Chem 1998; 44: 2506\u20132510.","journal-title":"Clin Chem"},{"key":"BFbmt2010315_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation. Ann Intern Med 1993; 118: 255\u2013267.","journal-title":"Ann Intern Med"},{"key":"BFbmt2010315_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1365-2257.2006.00754.x","volume":"28","author":"AL Lobashevsky","year":"2006","unstructured":"Lobashevsky AL, Senkbeil RW, Townsend JE, Mink CA, Thomas JM . Quantitative analysis of chimerism using a short tandem repeat method on a fluorescent automated DNA sequencer. Clin Lab Haematol 2006; 28: 40\u201349.","journal-title":"Clin Lab Haematol"},{"key":"BFbmt2010315_CR17","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010315_CR18","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2005; 11: 945\u2013955.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010315_CR19","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"R Gray","year":"1988","unstructured":"Gray R . A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141\u20131154.","journal-title":"Ann Stat"},{"key":"BFbmt2010315_CR20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/sim.1070","volume":"21","author":"JB Choudhury","year":"2002","unstructured":"Choudhury JB . Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 2002; 21: 1129\u20131144.","journal-title":"Stat Med"},{"key":"BFbmt2010315_CR21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"J Fine","year":"1999","unstructured":"Fine J, Gray R . A proportional hazards model for the subdistribution of a competing risk. JASA 1999; 94: 496\u2013509.","journal-title":"JASA"},{"key":"BFbmt2010315_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bbmt.2006.08.037","volume":"13","author":"T Madden","year":"2007","unstructured":"Madden T, de Lima M, Thapar N, Nguyen J, Roberson S, Couriel D et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: A comparison with every 6-h dosing. Biol Blood Marrow Transplant 2007; 13: 56\u201364.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010315_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bbmt.2007.10.028","volume":"14","author":"M Geddes","year":"2008","unstructured":"Geddes M, Kangarloo B, Naveed F, Quinlan D, Chaudhry MA, Stewart D et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008; 14: 220\u2013228.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010315_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/sj.bmt.1702377","volume":"25","author":"M Hassan","year":"2000","unstructured":"Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C et al. The effect of busulfan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915\u2013924.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010315_CR25","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","volume":"101","author":"GB McDonald","year":"2003","unstructured":"McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043\u20132048.","journal-title":"Blood"},{"key":"BFbmt2010315_CR26","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.bbmt.2007.03.012","volume":"13","author":"JS McCune","year":"2007","unstructured":"McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B et al. Cyclophosphamide following targeted oral busulfan and conditioning for hematopoietic cell transplantation: Pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007; 13: 853\u2013862.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010315_CR27","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood-2002-02-0527","volume":"100","author":"HJ Deeg","year":"2002","unstructured":"Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100: 1201\u20131207.","journal-title":"Blood"},{"key":"BFbmt2010315_CR28","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.bbmt.2006.05.015","volume":"12","author":"AS Artz","year":"2006","unstructured":"Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 954\u2013964.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010315_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/bmt.2008.300","volume":"43","author":"R Guilfoyle","year":"2009","unstructured":"Guilfoyle R, Demers A, Bredeson C, Richardson E, Rubinger M, Szwajcer D et al. Performance status, but not Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 2009; 43: 133\u2013139.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010315_CR30","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","volume":"25","author":"JL Sorror","year":"2007","unstructured":"Sorror JL, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246\u20134254.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010315_CR31","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1200\/JCO.2005.05.694","volume":"23","author":"H Wallen","year":"2005","unstructured":"Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005; 23: 3429\u20133446.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2010315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2010315","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2010315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T13:13:34Z","timestamp":1648041214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2010315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,6]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["BFbmt2010315"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2010.315","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,6]]},"assertion":[{"value":"3 June 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Janelle Perkins, Teresa Field and Claudio Anasetti received research support from PDL Biopharma for this project.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}